Report Library
All Reports
Early 2016 Outlook Report
February 05, 2016
In this report, we cover catalysts from 22 drugs, devices and diagnostics expected to occur in early 2016. We have also included a list of
Large Impact catalysts in
the drug and device/diagnostic areas through early 2016 from our sister product, CatalystTracker. In addition, each drug’s likelihood of
Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are
provided.
Our Q4 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 6 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 75% of catalyst outcomes that occurred in Q4 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
Our Q4 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 6 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 75% of catalyst outcomes that occurred in Q4 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: |
Acute Myelogenous Leukemia (AML)
Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)) Cardiac Valve Surgery Chemotherapy Induced Nausea and Vomiting (CINV) Coronary Artery Disease Dyslipidemia / Hypercholesterolemia Endometriosis Hepatic Fibrosis HIV / AIDS Treatment Hyperparathyroidism (Secondary) Indolent Non-Hodgkin's Lymphoma - iNHL Migraine and Other Headaches Multiple Myeloma (MM) Osteoarthritis Osteoporosis / Osteopenia Parkinson's Disease (PD) Peripheral Arterial Disease (PAD) Psoriasis Rheumatoid Arthritis (RA) Substance Use Disorder Venous Thromboembolism (VTE) |
Additional Resources: